Monopar Therapeutics - MNPR
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| May 15, 2026 | SCHEDULE 13G | Saturn V Capital Management LP | 5.2% | 345,626 | View |
| May 15, 2026 | SCHEDULE 13G | Xiaoying Tian | 5.2% | 345,626 | View |
| May 13, 2026 | SCHEDULE 13G/A | Adage Capital Management, L.P. | 6.23% | 424,195 | View |
| May 13, 2026 | SCHEDULE 13G/A | Robert Atchinson | 6.23% | 424,195 | View |
| May 13, 2026 | SCHEDULE 13G/A | Phillip Gross | 6.23% | 424,195 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | RA Capital Management, L.P. | 9.9% | 667,632 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Peter Kolchinsky | 9.9% | 667,632 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Rajeev Shah | 9.9% | 667,632 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | RA Capital Healthcare Fund, L.P. | 9.9% | 667,632 | View |
| Feb 06, 2026 | SCHEDULE 13G/A | AstraZeneca PLC | 7.8% | 522,667 | View |
| Feb 06, 2026 | SCHEDULE 13G/A | Alexion Pharmaceuticals, Inc. | 7.8% | 522,667 | View |
| Jan 30, 2026 | SCHEDULE 13D/A | — | — | — | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.